Affinity binding of antibodies to supermacroporous cryogel adsorbents with immobilized protein A for removal of anthrax toxin protective antigen

Biomaterials
Ganesh C IngavleSusan R Sandeman

Abstract

Polymeric cryogels are efficient carriers for the immobilization of biomolecules because of their unique macroporous structure, permeability, mechanical stability and different surface chemical functionalities. The aim of the study was to demonstrate the potential use of macroporous monolithic cryogels for biotoxin removal using anthrax toxin protective antigen (PA), the central cell-binding component of the anthrax exotoxins, and covalent immobilization of monoclonal antibodies. The affinity ligand (protein A) was chemically coupled to the reactive hydroxyl and epoxy-derivatized monolithic cryogels and the binding efficiencies of protein A, monoclonal antibodies to the cryogel column were determined. Our results show differences in the binding capacity of protein A as well as monoclonal antibodies to the cryogel adsorbents caused by ligand concentrations, physical properties and morphology of surface matrices. The cytotoxicity potential of the cryogels was determined by an in vitro viability assay using V79 lung fibroblast as a model cell and the results reveal that the cryogels are non-cytotoxic. Finally, the adsorptive capacities of PA from phosphate buffered saline (PBS) were evaluated towards a non-glycosylated, plant-deri...Continue Reading

References

Jan 1, 1978·Journal of Immunological Methods·D M Gersten, J J Marchalonis
Apr 25, 1977·Biochemical and Biophysical Research Communications·N KoideT Muramatsu
May 15, 1990·Analytical Chemistry·F V BrightK S Litwiler
Jan 1, 1997·Biosensors & Bioelectronics·G P AndersonK D King
Mar 6, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·J Turková
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Nov 5, 2002·Analytical Biochemistry·Philipp AngenendtDolores J Cahill
Sep 11, 2003·Biotechnology and Bioengineering·R DanczykA Rundell
Oct 22, 2003·Biosensors & Bioelectronics·Lorena TedeschiAndrea Mencaglia
Mar 17, 2004·Biosensors & Bioelectronics·Kim E Sapsford, Frances S Ligler
Oct 13, 2007·Journal of Biomaterials Science. Polymer Edition·Nimet BölgenErhan Pişkin
Mar 19, 2008·Biomacromolecules·Viktoria WeberDieter Falkenhagen
Apr 3, 2008·Journal of Separation Science·Haixiang SunHuanlin Chen
Apr 9, 2008·Journal of Chromatography. a·Nilay BereliAdil Denizli
Nov 4, 2008·Colloids and Surfaces. B, Biointerfaces·Gözde BaydemirAdil Denizli
Dec 12, 2012·Advances in Colloid and Interface Science·Vladimir M Gun'koSergey V Mikhalovsky
Jan 23, 2014·Emerging Infectious Diseases·Katherine A HendricksUNKNOWN Workgroup on Anthrax Clinical Guidelines
May 9, 2014·Infection and Drug Resistance·Carlos E Kummerfeldt

❮ Previous
Next ❯

Citations

Dec 22, 2015·Biosensors & Bioelectronics·Maria Serena ChiriacòGiuseppe Maruccio
Dec 17, 2015·Environmental Science and Pollution Research International·Hary DemeyIngrid Bazin
Apr 20, 2019·Gels·Yeşeren Saylan, Adil Denizli
Dec 11, 2019·Pharmaceutics·Bolat SultankulovArman Saparov
Sep 15, 2019·Analytica Chimica Acta·María Vergara-BarberánJosé Manuel Herrero-Martínez
Apr 5, 2021·Materials Science & Engineering. C, Materials for Biological Applications·Flavia BonalumiSusan Sandeman
Dec 9, 2019·ACS Biomaterials Science & Engineering·Heta ThakarAkshay Srivastava

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

© 2022 Meta ULC. All rights reserved